SESSION TITLE: Biotechnology
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Real-world adherence to inhaled and oral therapies for cystic fibrosis (CF) patients remains discouragingly low, ranging 31-53% for inhaled antibiotics. Programs to enhance adherence, including comprehensive behavioral interventions with adolescents, have met with mixed success. Blue-tooth enabled technology allows for the advancement of patient medication adherence monitoring and intervention.